Brochure
4 Jul 2024

Introduction

PDF 15.8 MB

Established in 2002, Hangzhou FST Pharmaceutical focuses on advanced intermediates, APIs, and nutraceuticals. In 2022, it was acquired by Shanghai Eyougene Biotechnology, founded by top Fudan University graduates. Eyougene excels in digital CDMO services for advanced intermediates and new materials.  The group has R&D centers in Shanghai, Xi'an, and Wuhan, with 382 employees, including 169 R&D and QA professionals. The main products include cardiovascular, gastrointestinal, and weight control products. 
 Located in Jiande Hangzhou, the factory complies with GMP and holds ISO9001:2000, ISO14001, and OHSAS18001 certifications. Eyougene is committed to life science innovation for human health.
Here is the profile of Eyougene and FST.  You can find the introduction of company, technology, products,production system and business partners. 

Content provided by our supplier

Hangzhou Fst Pharmaceutical Co.,Ltd

  • CN
  • 2015
    On CPHI since
  • 3
    Certificates
  • 250 - 499
    Employees
Company types
CMO/CDMO
Manufacturer/Innovator
Primary activities
Agrochemical
Animal Health
API Producer
Chemical Development
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Intermediates Manufacturer
Nutraceuticals

Other Content from Hangzhou Fst Pharmaceutical Co.,Ltd ()